Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.
Renal impairment categories as defined by the cited product label
Renal action or finding
Renal impairment does not require an automatic abaloparatide dose reduction. Severe impairment increases exposure and warrants monitoring for adverse reactions.
Limits and monitoring
Assess tolerance and calcium-related adverse effects. No dialysis schedule is established here.
Belzutifan has no routine renal reduction, including in ESRD. At MDRD eGFR 15-29 mL/min, monitor closely for adverse reactions and adjust for toxicity.
Limits and monitoring
Use product-specific instructions for anemia, hypoxia and other toxicities.
At CrCl 30 to below 90 mL/min no renal adjustment is required for the long-acting injection combination. With severe impairment or ESRD, increase monitoring for adverse effects.
Limits and monitoring
Verify the long-acting injectable regimen and the instructions for missed doses.
For extended treatment of symptomatic VTE in adults with cancer and CrCl below 30 mL/min, use anti-Xa monitoring to determine dose. Target 0.5-1.5 units/mL at 4-6 hours after dosing after 3-4 doses.
Limits and monitoring
This target is specific to the stated population and indication. Verify bleeding risk and neuraxial procedure timing separately.
Severe renal dysfunction and dialysis increase the risk of denosumab-associated hypocalcemia. Monitor calcium and assess calcium and vitamin D intake, especially at CrCl below 30 mL/min or during dialysis.
Limits and monitoring
Verify the oncology Xgeva product and indication. Comparable exposure does not eliminate the risk of hypocalcemia.
Renal impairment categories as defined by the cited product label
Renal action or finding
Renal impairment decreases valproate protein binding, which can change the relationship between total concentration and pharmacologically active free drug.
Limits and monitoring
Interpret total levels alongside clinical response and toxicity. Verify the delayed-release formulation.
Renal impairment categories as defined by the cited product label
Renal action or finding
Mild impairment has no special adjustment. In moderate or severe impairment, doses above ezetimibe 10 mg/simvastatin 20 mg require caution and close monitoring.
Limits and monitoring
The dose is written in ezetimibe/simvastatin order. Assess muscle symptoms and interacting drugs.
